South West Sydney Clinical Campuses

P462 Upfront infliximab dose intensification for secondary loss of response in IBD: similar efficacy to dose interval shortening with the added advantage of early clinical and pharmacokinetic predictors of response

Srinivasan A; De Cruz P; Sam M; Toong C; van Langenberg D, 2022, 'P462 Upfront infliximab dose intensification for secondary loss of response in IBD: similar efficacy to dose interval shortening with the added advantage of early clinical and pharmacokinetic predictors of response', Journal of Crohn's and Colitis, vol. 16, pp. i437 - i438, 10.1093/ecco-jcc/jjab232.589

Back to Top